Rini BI - Search Results

1

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.

Rini BI, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, George S, Powles T, Donskov F, Tykodi SS, Pal SK, Gupta S, Lee CW, Jiang R, Tannir NM. Rini BI, et al. J Immunother Cancer. 2022 Dec;10(12):e005445. doi: 10.1136/jitc-2022-005445. J Immunother Cancer. 2022. PMID: 36549781 Free PMC article. Clinical Trial.

2

A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.

Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. Desai AA, et al. Among authors: rini bi. Cancer. 2002 Oct 15;95(8):1629-36. doi: 10.1002/cncr.10847. Cancer. 2002. PMID: 12365009 Free article. Clinical Trial.

3

A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.

Rini BI, Weinberg V, Small EJ. Rini BI, et al. Cancer. 2005 Feb 1;103(3):553-8. doi: 10.1002/cncr.20795. Cancer. 2005. PMID: 15612026 Free article. Clinical Trial.

4

Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.

Rini BI, Sosman JA, Motzer RJ. Rini BI, et al. BJU Int. 2005 Aug;96(3):286-90. doi: 10.1111/j.1464-410X.2005.05616.x. BJU Int. 2005. PMID: 16042715 Retracted. Review. No abstract available.

5

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Motzer RJ, et al. Among authors: rini bi. J Clin Oncol. 2006 Jan 1;24(1):16-24. doi: 10.1200/JCO.2005.02.2574. Epub 2005 Dec 5. J Clin Oncol. 2006. PMID: 16330672 Clinical Trial.

6

Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.

Rini BI, Weinberg V, Dunlap S, Elchinoff A, Yu N, Bok R, Simko J, Small EJ. Rini BI, et al. Cancer. 2006 Feb 1;106(3):566-75. doi: 10.1002/cncr.21661. Cancer. 2006. PMID: 16369983 Free article. Clinical Trial.

7

Sunitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Motzer RJ, et al. Among authors: rini bi. JAMA. 2006 Jun 7;295(21):2516-24. doi: 10.1001/jama.295.21.2516. JAMA. 2006. PMID: 16757724 Clinical Trial.

8

Laparoscopic versus open cytoreductive nephrectomy in advanced renal-cell carcinoma.

Eisenberg MS, Meng MV, Master VA, Stoller ML, Rini BI, Carroll PR, Kane CJ. Eisenberg MS, et al. Among authors: rini bi. J Endourol. 2006 Jul;20(7):504-8. doi: 10.1089/end.2006.20.504. J Endourol. 2006. PMID: 16859465

9

Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.

Shaheen PE, Rini BI, Bukowski RM. Shaheen PE, et al. Among authors: rini bi. Clin Genitourin Cancer. 2006 Jun;5(1):78-81. doi: 10.3816/CGC.2006.n.021. Clin Genitourin Cancer. 2006. PMID: 16859583

10

The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.

Choueiri TK, Bukowski RM, Rini BI. Choueiri TK, et al. Among authors: rini bi. Semin Oncol. 2006 Oct;33(5):596-606. doi: 10.1053/j.seminoncol.2006.06.003. Semin Oncol. 2006. PMID: 17045089 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

477 results

Search Page